Still negotiating in multiple countries apparently
Melbourne, Australia; 5 July 2021: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announces it has received several infringement notices from the TGA with respect to alleged advertising of VIRALEZE™ antiviral nasal spray to Australian consumers. Upon becoming aware of these alleged issues, Starpharma immediately acted to prevent Australian consumers from accessing the alleged infringing information from the VIRALEZE™ product website (viraleze.co), Starpharma’s corporate website (starpharma.com), and its YouTube channel. The total amount of the infringement notices is $93,240.
Starpharma takes its responsibilities and obligations for compliance with the Therapeutic Goods Act very seriously. The Company will work closely with the TGA to resolve the current matter and how to balance the need to provide information to its shareholders about key company milestones, products and activities, with the requirements of the Act in relation to advertising in Australia.
Starpharma has successfully developed and registered multiple products, including VIRALEZE™, in international markets. Products containing SPL7013 are already registered for sale in more than 45 countries, including the UK, Europe, Japan, Australia, South Africa, New Zealand and a number of countries in South East Asia. VIRALEZE™ is one of seven products Starpharma has either on market or in clinical development, including four clinical stage oncology products, one of which is being developed under a multi-product licence with a global pharmaceutical company.
VIRALEZE™ is registered for sale in Europe and India, and the product website for VIRALEZE™ (viraleze.co) remains accessible to consumers outside Australia.
Starpharma is currently negotiating distribution and marketing arrangements for VIRALEZE™ in a number of countries which include India, various European countries and other international regions.
Well at least we know we aren't the only one coping fines ...
